NEW YORK (TheStreet) -- Jazz Pharmaceuticals (JAZZ) "did not hit the numbers, so the stock is down," TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, said on CNBC's "Cramer's Stop Trading" segment.
The company missed analysts' estimates for its top- and bottom-line results. Cramer said he's highlighting Jazz Pharmaceuticals because of how poorly biotechnology stocks have performed over the past two months.
Turning to WhiteWave Foods (WWAV), "I thought that quarter was amazing," he said of the company's top and bottom line earnings beat.
He added that Hain Celestial Group (HAIN) is also doing very well, and its CEO Irwin Simon is "too clever" for the short-sellers.